GlobalData on MSN13d
AbbVie and Simcere Zaiming link to develop trispecific antibody
The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...
PMLiVE13d
AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn
AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...
Morningstar15d
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an ...
AbbVie, Simcere Zaiming announce partnership to develop SIM0500
AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced an option to license agreement to develop SIM0500, ...
Business Insider15d
AbbVie And Simcere Zaiming Partner To Develop Innovative Cancer Drug SIM0500
(RTTNews) - AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement to advance SIM0500, an investigational drug ...
Crain's Chicago Business15d
AbbVie keeps adding cancer treatments with $1B licensing deal for new drug
In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...
Morningstar15d
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...